Banzhaf CA, Phothong W, Suku MLH, et al. - In the present study, the researchers examined basal cell carcinomas (BCC) response and tolerability following combined ablative fractional laser (AFL) and ingenol mebutate (IM) treatment of low-risk BCCs. For this investigation, 20 patients with histologically confirmed superficial and nodular BCCs were treated with combined fractional CO₂-laser (10,600 nm) and IM 0.015% or 0.05%, the concentration depending on anatomical location. According to results, 18/20 patients received a second treatment on day 29 due to clinically detected residual BCC through optical coherence tomography (OCT) or reflectance confocal microscopy (RCM). In five of 20 cases, OCT and RCM presented subclinical BCCs. At day 90, the overall histological cure rate was 70%, corresponding to clinical and OCT/RCM cure rates, and there was a substantial agreement between evaluation methods. LSRs were tolerable, but in the majority of cleared patients, scarring was observed. Two combined AFL and IM treatments show potential for acceptable tolerability in treating low-risk BCCs. OCT and RCM show promise at a short-term follow-up to detect subclinical BCCs.